11170376001
Roche
Anti-Bromodeoxyuridine
from mouse IgG1 (clone: BMC9318)
Synonim(y):
anti-BrdU, antibody
Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
About This Item
Kod UNSPSC:
12352203
Polecane produkty
pochodzenie biologiczne
mouse
Poziom jakości
białko sprzężone
unconjugated
forma przeciwciała
purified immunoglobulin
rodzaj przeciwciała
primary antibodies
klon
BMC9318, monoclonal
Próba
90% (HPLC and SDS-PAGE)
Postać
solution
opakowanie
pkg of 50 μg (500 μl)
producent / nazwa handlowa
Roche
izotyp
IgG1
temp. przechowywania
−20°C
Opis ogólny
Anti-Bromodeoxyuridine is a monoclonal antibody to 5-bromo-2′-deoxyuridine-5′-monophosphate.
Specyficzność
The antibody specifically binds to bromodeoxyuridine and crossreacts with iodouridine (10%). Anti-bromo-deoxyuridine does not crossreact with fluorodeoxy-uridine, nor with any endogenous cellular components such as thymidine or uridine.
Immunogen
The epitope is apparently inside the DNA helix. DNA has to be denatured to ssDNA before antibody efficiently binds to DNA-BrdU.
Zastosowanie
Anti-bromodeoxyuridine (Anti-BrdU) antibody is suitable for monitoring proliferating cells in blood, tissues, and tumors, as well as for determining BrdU incorporation on a single-cell level using:
- Flow cytometry
- Immunohistocytochemistry
- Cryosections
- Paraffin sections
Jakość
The antibody is ≥90% pure as determined by SDS-PAGE with Coomassie-blue staining, and by HPLC.
Charakterystyka techniczna
Preparation: BALB/c mice were immunized with a bromodeoxyuridine-bovine serum albumin conjugate. Lymphocytes isolated from the spleen were fused with Ag8.653 myeloma cells to create the BMC 9318 clone. The antibody was produced in ascites in BALB/c mice and purified by ion-exchange chromatography.
No. of tests: 250 (Flow cytometry)
No. of tests: 250 (Flow cytometry)
Postać fizyczna
Solution, stabilized with phosphate buffered saline, pH 7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) gelatin.
Uwaga dotycząca przygotowania
Working concentration: Flow cytometry: 2 μg/ml (0.2 μg/100 μl/106 cells); Immunohistocytochemistry: 6 μg/ml
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Working concentration of conjugate depends on application and substrate. Dilutions should be made in PBS (pH 7.4) containing 0.1% BSA to maintain stability of the antibody.
Komentarz do analizy
Anti-Bromodeoxyuridine shows 10% cross reaction with iodo-deoxyuridine, but no cross reaction to fluoro-deoxyuridine.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
No cross reaction to any endogenous thymidine or uridine.
Cross reactivity with 5-Br-UTP has not been tested but it is suggested that there is a good chance for reaction, because the only difference is an absent hydroxyl group on the ribose distal to the bromine substitution.
Inne uwagi
For life science research only. Not for use in diagnostic procedures.
This page may contain text that has been machine translated.
Not finding the right product?
Try our Narzędzie selektora produktów.
Kod klasy składowania
12 - Non Combustible Liquids
Klasa zagrożenia wodnego (WGK)
nwg
Temperatura zapłonu (°F)
No data available
Temperatura zapłonu (°C)
No data available
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Klienci oglądali również te produkty
Derek C Adams et al.
American journal of physiology. Renal physiology, 297(3), F809-F815 (2009-06-19)
Long-term pulse chase experiments previously identified a sizable population of BrdU-retaining cells within the renal papilla. The origin of these cells has been unclear, and in this work we test the hypothesis that they become quiescent early during the course
Wouter Laurentius Smit et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(41), 25560-25570 (2020-09-30)
Deregulated global mRNA translation is an emerging feature of cancer cells. Oncogenic transformation in colorectal cancer (CRC) is driven by mutations in APC, KRAS, SMAD4, and TP53, known as the adenoma-carcinoma sequence (ACS). Here we introduce each of these driver
Erika A Correll et al.
IBRO neuroscience reports, 10, 31-41 (2021-04-17)
It has been demonstrated that adult born granule cells are generated after traumatic brain injury (TBI). There is evidence that these newly generated neurons are aberrant and are poised to contribute to poor cognitive function after TBI. Yet, there is
Xuexiao Li et al.
Cell death discovery, 8(1), 323-323 (2022-07-17)
Myelodysplastic syndromes (MDS) are characterized by daunting genetic heterogeneity and a high risk of leukemic transformation, which presents great challenges for clinical treatment. To identify new chemicals for MDS, we screened a panel of FDA-approved drugs and verified the neutrophil
Victoria Sofía Berenice Wies Mancini et al.
Glia, 67(2), 291-308 (2018-11-21)
Multiple sclerosis (MS) is one of the most common causes of progressive disability affecting young people with very few therapeutic options available for its progressive forms. Its pathophysiology involves demyelination and neurodegeneration apparently driven by microglial activation, which is physiologically
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej